Por favor, use este identificador para citar o enlazar este ítem: https://repositorio.uca.edu.ar/handle/123456789/13680
Campo DC Valor Lengua/Idioma
dc.contributor.authorPandi Perumal, Seithikurippu R.es
dc.contributor.authorCardinali, Daniel Pedroes
dc.contributor.authorReiter, R.es
dc.contributor.authorBrown, Gregory M.es
dc.date.accessioned2022-03-25T11:37:51Z-
dc.date.available2022-03-25T11:37:51Z-
dc.date.issued2020-
dc.identifier.citationPandi Perumal, S. R. et al. Low melatonin as a contributor to SARS-CoV-2 disease [en línea]. Melatonin Research. 2020, 3 (4). doi: 10.32794/mr11250079. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13680es
dc.identifier.urihttps://repositorio.uca.edu.ar/handle/123456789/13680-
dc.description.abstractAbstract: That the pineal gland is a source of melatonin is widely known; however, by comparison, few know of the much larger pool of extrapineal melatonin. That pool is widely distributed in all animals, including those that do not have a pineal gland, e.g., insects. Extrapineal melatonin is not released into the blood but is used locally to function as an antioxidant, anti-inflammatory agent, etc. A major site of action of peripherally-produced melatonin is the mitochondria where it neutralizes reactive oxygen species (ROS) that are generated during oxidative phosphorylation. Its role also includes major actions as an immune modulator reducing overreactions to foreign agents while simultaneously boosting immune processes. During a pandemic such as coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, melatonin is capable of suppressing the damage inflicted by the cytokine storm. The implications of melatonin in susceptibility and treatment of COVID-19 disease are discussed.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.rightsAcceso abierto*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.sourceMelatonin Research. 2020, 3 (4)es
dc.subjectCOVID-19es
dc.subjectSARS-CoV-2es
dc.subjectCORONAVIRUSes
dc.subjectMELATONINAes
dc.subjectMITOCONDRIASes
dc.subjectCITOQUINASes
dc.titleLow melatonin as a contributor to SARS-CoV-2 diseasees
dc.typeArtículoes
dc.identifier.doi10.32794/mr11250079-
uca.disciplinaMEDICINAes
uca.issnrd1es
uca.affiliationFil: Pandi Perumal, Seithikurippu R. Somnogen Canada Inc; Canadáes
uca.affiliationFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentinaes
uca.affiliationFil: Reiter, R. UT Health San Antonio. Department of Cell Systems and Anatomy; Estados Unidoses
uca.affiliationFil: Brown, Gregory M. Univeridad de Toronto. Centro para la Adicción y la Salud Mental. Ciencias Moleculares del Cerebro; Canadáes
uca.versionpublishedVersiones
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.languageiso639-1en-
crisitem.author.deptConsejo Nacional de Investigaciones Científicas y Técnicas-
crisitem.author.deptInstituto de Investigaciones Biomédicas - BIOMED-
crisitem.author.deptFacultad de Ciencias Médicas-
crisitem.author.orcid0000-0002-0813-9088-
crisitem.author.parentorgFacultad de Ciencias Médicas-
crisitem.author.parentorgPontificia Universidad Católica Argentina-
Aparece en las colecciones: Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
low-melatonin-contributor.pdf308,45 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem

Visualizaciones de página(s)

143
comprobado en 25-abr-2024

Descarga(s)

91
comprobado en 25-abr-2024

Google ScholarTM

Consultar


Altmetric


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons